Michael Pisetsky Sells 3,726 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,726 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $14.63, for a total value of $54,511.38. Following the sale, the senior vice president directly owned 280,509 shares of the company’s stock, valued at $4,103,846.67. The trade was a 1.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Down 0.1%

Shares of SiBone stock opened at $14.81 on Friday. The stock has a market capitalization of $656.82 million, a P/E ratio of -37.97 and a beta of 0.67. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20. The stock has a 50 day moving average price of $13.38 and a two-hundred day moving average price of $16.10. SiBone has a 12-month low of $11.48 and a 12-month high of $21.89.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The firm had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. Equities analysts expect that SiBone will post -0.44 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SIBN shares. Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. TD Cowen reduced their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Finally, Truist Financial reissued a “buy” rating and issued a $18.00 price objective (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Institutional Investors Weigh In On SiBone

Several hedge funds have recently modified their holdings of the business. First Light Asset Management LLC boosted its position in shares of SiBone by 6.4% in the first quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock valued at $67,611,000 after acquiring an additional 320,286 shares during the period. American Century Companies Inc. boosted its position in shares of SiBone by 22.5% in the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock valued at $41,777,000 after acquiring an additional 521,683 shares during the period. Vanguard Group Inc. raised its stake in shares of SiBone by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock valued at $49,331,000 after purchasing an additional 11,566 shares in the last quarter. Granahan Investment Management LLC lifted its position in SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after purchasing an additional 858,942 shares during the period. Finally, Nuveen LLC lifted its position in SiBone by 5.1% in the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock worth $28,041,000 after purchasing an additional 69,229 shares during the period. 98.11% of the stock is owned by institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.